Abstract
Antipsychotic drugs are the first line of treatment in schizophrenia; although antipsychotic responses indicate a wide interindividual variety in patients with schizophrenia. This study aimed to investigate the association between four polymorphisms in DRD2, DRD4 and COMT genes and their gene-gene interactions with antipsychotic treatment response in patients with schizophrenia. A total of 101 patients with schizophrenia were recruited and stratified in treatment responder and treatment resistant groups based on the published criteria of resistant to treatment using PANSS. Clinical and demographic factors were analyzed. Genomic DNA was extracted from whole blood and genoty** for the four polymorphisms were done by ARMS-PCR, PCR-RFLP and gap-PCR. Gene-gene interactions were analyzed by logistic regression. In case of DRD2 A-241G, G allele was significantly associated with resistant to treatment. Regarding DRD4 120-bp duplication, 240/240 genotype was significantly associated with resistant to treatment comparing to other genotypes in a dominant model. The genotype combination of DRD4 240/240 and COMT Val/Val was significantly associated with treatment resistant. Among DRD2 AA genotype, COMT met allele carriers which also had a 120 bp allele of DRD4 had a significantly better response to antipsychotics. Moreover, analysis of clinical and demographic factors demonstrated a significantly longer duration of hospitalization and higher chlorpromazine-equivalent daily dose in resistant to treatment patients. Discovering the polymorphisms which effect treatment response to antipsychotics will provide the possibility of genetic screening before starting an antipsychotic treatment which enhances the chance of responding to antipsychotics and decreases drugs side effects and costs.
Similar content being viewed by others
Background
Schizophrenia (SCZ) is a chronic, hereditary and disabling neuropsychiatric disorder with a worldwide prevalence of approximately 1% [1, 2]. In the etiology of SCZ, genetic factors are thought to play an important role, the heritability currently ranges from 64 to 81%; although, genetic mechanisms remain unclear [2,3,4]. The mainstay of schizophrenia treatment has been antipsychotic drugs over the past 60 years; however, clinical response differs significantly between patients, with an overall response rate of 50–70% [1, 5,6,7]. Many of patients with schizophrenia discontinue or switch drug regimens due to lack of treatment efficacy and/or drugs adverse side effects. In this view, there is a great need for the identification of predictive clinical and biological markers of treatment consequence [8, 9]. Pharmacogenetic biomarkers focus to predict which patients could improve with specified drugs according to genetic variants. Thus, genotype-based customized drug treatments may allow optimizing the antipsychotic treatment, while hel** to minimize drugs side effects [10, 11].
To date, pharmacogenomics studies of response to treatment in schizophrenia, have typically focused on genes encoding for drug targets, called pharmacodynamics related genes. Many of the research investigating the association of pharmacodynamic genes with antipsychotic treatment response have concentrated on dopaminergic pathways, one of the primary mechanisms of function of antipsychotics, especially the gene coding for the dopamine D2 receptor(DRD2 gene), which is a binding object for all available antipsychotic drugs. Dopaminergic gene SNPs are strongly related to drug sensitivity of antipsychotics; for example, several studies have indicated positive associations between DRD2 gene and antipsychotic response [10,11,12,13,14].
Lingyue Ma and et al. by a systematic review and meta-analysis indicated that for Asian patients, at rs1799978(A241G) in DRD2 gene AA genotype had a significantly greater improvement after risperidone therapy [33]). The ARMS-PCRs were performed in two 15ul reactions for each patient, which contained an initial denaturation at 95 °C for 2 min followed by 35–36 cycles of denaturing at 95 °C for 30 s, annealing at 65 °C for 30s and extending at 72 °C for 45s. After that, a final extension at 72 °C for 5 min was applied.
COMT rs4680 was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR- RFLP). The PCR was conducted in a 15ul reaction system which included an initial denaturation at 95 °C for 2 min followed by 35 cycles of denaturing at 95 °C for 30 s, annealing at 61 °C for 30 s and extending at 72 °C for 30s. After 35 cycles, it experienced a final extension at 72 °C for 5 min. NIaIII restriction enzyme was used for digestion; as explained by Qianqian He and et al [34]. Genoty** of 120-bp duplication polymorphism in DRD4 was performed using the Gap-PCR (primers by [35]). The PCR was carried out in a15ul reaction system which contained a first denaturation at 95 °C for 2 min followed by 30 cycles of denaturing at 95 °C for 30 s, annealing at 66 °C for 30 s and extending at 72 °C for 55s. After 30 cycles, a final extension at 72 °C for 5 min was done.
Statistical analysis
All data analysis was conducted using Statistical Package for the Social Sciences SPSS, Version 26. Continuous variables were expressed in the form of mean ± standard deviation. Kolmogorov–Smirnov test was applied to check whether the data were normally distributed; which normally distributed and abnormally distributed data between two groups were calculated respectively by t-test and Mann-Whitney U test. In order to assess the association between categorical variables of clinical parameters and genotype associations chi-square test was performed. Associations between polymorphisms and antipsychotic treatment response were analyzed under five genetic models including homozygous model, heterozygous model, recessive model, dominant model and co-dominant model. Logistic regression analysis was carried out in order to analyze these five genetic models. Adjusted odds ratios, adjusted P-values and 95% confident interval (95%CI) were calculated. Furthermore, logistic regression analysis was used to examine the effect of interaction among polymorphisms on antipsychotic treatment response. P < 0.05 was considered as statistical significance in all tests.
Gpower software version 3.1.9.7 was applied in order to analyze the power of logistic regression. According to Chen et al., 2010 [36] effect size in logistic regression can be classified as follows:
-
Odds Ratio < 1.68 - Very small.
-
1.68 ≤ Odds Ratio < 3.47 - Small.
-
3.47 ≤ Odds Ratio < 6.71 - Medium.
-
Odds Ratio ≥ 6.71 – Large.
The power analysis demonstrated that a sample size of 101 is sufficient to reveal a medium to large effect size with a minimum power of 80% at a significance level of 5%.
Results
Clinical and demographic characteristics of patients
One hundred and one patients with schizophrenia were included in this study (75 men and 26 women), which among them 51 patients were classified in the treatment-responder group and 50 patients met the criteria for treatment-resistance. There were significant differences between two groups in marital status, smoking, duration of hospitalization, chlorpromazine-equivalent daily dose and total PANSS score(Table 1). With regarding to the clinical characteristics, significantly longer duration of hospitalization, higher PANSS score and also higher chlorpromazine-equivalent daily dose were observed in treatment-resistant group(Table 1). Furthermore, married and smoker patients were significantly more in the treatment-responder group comparing to the treatment-resistant group.
The frequently prescribed antipsychotics were perphenazine(47%), olanzapine(37%), risperidone(32%), quetiapine(26%) and haloperidol (24%).
Genetic analysis
Genotypic and allelic associations
The population was in Hardy-Weinberg equilibrium for the four polymorphisms genotyped in this study (p > 0.05). The G allele of DRD2 A-241G was associated with increased risk of resistant to treatment when compared to A allele (OR(95%CI): 3.661,P = 0.02,Table 2). As for DRD4 120-bp duplication, there existed a considerable difference in allele distribution(P = 0.064,Table 2), indicating a higher frequency of 240-bp allele in treatment-resistant patients; although, the P value was not significant.
The logistic regression analysis revealed that regarding DRD4 120-bp duplication, patients with 120/120 and 240/120 had a lower risk of develo** resistant to treatment as compared to patients with 240/240 genotype(AOR(95%CI): 0.196, P value: 0.033, Table 3). Moreover, regarding DRD4 120-bp duplication, homozygous and heterozygous genetic models indicated relations with antipsychotic treatment response, however it did not reach the significance level(P = 0.055 and P = 0.053 Respectively.
Gene-gene interaction analysis
Whether the presence of three polymorphism’s genotypes could influence the risk for treatment resistant to antipsychotic drugs was determined between DRD4 120-bp duplication, COMT rs4680 and DRD2 A-241G. We carried out all possible subgroup analyses; which the significant interactions are indicated in Table 4. In the COMT Val/Val subset, we found significant association of the DRD4 genotype with antipsychotics treatment response; where the combination of COMT Val/Val genotype and DRD4 240/240 genotype had a high risk for develo** treatment- resistance(OR(95%CI) = 3.232(1.056–9.892), P = 0.04). Also, among patients with COMT Val/Met - Met/Met genotypes(Met allele carriers) those whose genotypes where AA for DRD2 A-241G were significantly more likely to respond to antipsychotic drugs as compared to other genotype combinations(OR(95%CI) = 2.540(1.138–5.668), P = 0.023).
Furthermore, analyzing the interactions of DRD2 A-241G and DRD4 120-bp duplication polymorphisms, revealed a significant association between DRD2 AA genotype and DRD4 120 bp allele carriers(DRD4 120/240 − 120/120), patients with this genotype combination had a significantly better respond to antipsychotics(OR(95%CI) = 3.000(1.279–7.035), P = 0.012).
Additionally, logistic regression analysis indicated a significant interaction among DRD2 A-241G, DRD4 120-bp duplication and COMT rs4680 polymorphism’s; where patients with AA − 120/240 or 120/120 - Val/Met or Met/Met showed a significantly better respond to antipsychotics when comparing to patients with GA or GG-240/240-Val/Val genotype(OR(95%CI) = 2.363(1.057–5.281), P = 0.036).
Discussion
The key findings of the present study were as follows. First, our genetic analysis for DRD2 A-241G(rs1799978) polymorphism detected a significantly higher frequency of G allele in resistant to treatment patients in comparison with responders. A possible explanation for this association could be that since DRD2 binds to dopamine and is a G-protein coupled receptor, A-241G polymorphism is considered to be related to DRD2 density and affinity [37]. Furthermore, regarding DRD2, it is recorded that this receptor lonely could adjust effects of atypical antipsychotics; suggesting that DRD2 plays a substantial role in patients response to atypical antipsychotics [44].
Our sample size was relatively small especially the subgroups in gene-gene interactions were small and a few genotypes had limited carriers(GG genotype of DRD2 A-241G polymorphism and GC of DRD2 rs1801028); also CC genotype of DRD2 rs1801028 was not observed in our sample. Furthermore, no multiple testing correction was used for P-values in gene-gene interaction analyses and we should mention the type I error possibility as a limitation. Besides, the studied population was only from one single ethnicity. Consequently, further investigations with larger sample sizes and meta-analyses, from various ethnicities analyzing several polymorphisms involved in pathways related to antipsychotics actions are warranted; in order to move toward personalized medicine in schizophrenia.
Conclusion
In summary, our results suggest that COMT, DRD2 and DRD4 genes together and DRD2 and DRD4 genes separately, may effect and predict antipsychotic treatment response in Iranian population. This kind of study may provide the possibility of genetic screening before starting a new antipsychotic trial, resulting in a better chance to achieve the most effective treatment for each patient in a shorter period of time, decreasing costs and minimizing adverse side effects of drugs.
Data availability
All data generated or analyzed during this study are included in this published article.
References
Yan P, Gao B, Wang S, Wang S, Li J, Song M. Association of 5-HTR2A T102C and A-1438G polymorphisms with clinical response to atypical antipsychotic treatment in schizophrenia: a meta-analysis. Neurosci Lett. 2022;770:136395. Epub 2021 Dec 14. PMID: 34919991.
Liu Y, Fu X, Tang Z, Li C, Xu Y, Zhang F, Zhou D, Zhu C. Altered expression of the CSMD1 gene in the peripheral blood of patients with schizophrenia. BMC Psychiatry. 2019;19(1):113. https://doi.org/10.1186/s12888-019-2089-4. PMID: 30987620; PMCID: PMC6466712.
Fu X, Zhang G, Liu Y, Zhang L, Zhang F, Zhou C. Altered expression of the DISC1 gene in peripheral blood of patients with schizophrenia. BMC Med Genet. 2020;21(1):194. https://doi.org/10.1186/s12881-020-01132-9. PMID: 33008326; PMCID: PMC7532617.
Jauhar S, Johnstone M, McKenna PJ, Schizophrenia. Lancet. 2022;399(10323):473–486. https://doi.org/10.1016/S0140-6736(21)01730-X. PMID: 35093231.
Zhang Y, Ren H, Wang Q, Deng W, Yue W, Yan H, Tan L, Chen Q, Yang G, Lu T, Wang L, Zhang F, Yang J, Li K, Lv L, Tan Q, Zhang H, Ma X, Yang F, Li L, Wang C, Zhang D, Zhao L, Wang H, Li X, Guo W, Hu X, Tian Y, Ma X, Li T. Chinese Antipsychotics Pharmacogenomics Consortium. Testing the role of genetic variation of the MC4R gene in Chinese population in antipsychotic-induced metabolic disturbance. Sci China Life Sci. 2019;62(4):535–43. https://doi.org/10.1007/s11427-018-9489-x. Epub 2019 Mar 26. PMID: 30929193.
Han M, Deng C. BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia. Neurosci Lett. 2020;726:133870. https://doi.org/10.1016/j.neulet.2018.10.015. Epub 2018 Oct 9. PMID: 30312750.
Huang E, Zai CC, Lisoway A, Maciukiewicz M, Felsky D, Tiwari AK, Bishop JR, Ikeda M, Molero P, Ortuno F, Porcelli S, Samochowiec J, Mierzejewski P, Gao S, Crespo-Facorro B, Pelayo-Terán JM, Kaur H, Kukreti R, Meltzer HY, Lieberman JA, Potkin SG, Müller DJ, Kennedy JL. Catechol-O-Methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in Schizophrenia and Schizo-Affective disorder patients: a Meta-analysis. Int J Neuropsychopharmacol. 2016;19(5):pyv132. https://doi.org/10.1093/ijnp/pyv132. PMID: 26745992; PMCID: PMC4886669.
Maffioletti E, Valsecchi P, Minelli A, Magri C, Bonvicini C, Barlati S, Sacchetti E, Vita A, Gennarelli M. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in patients with schizophrenia. Drug Dev Res. 2020;81(6):754–61. https://doi.org/10.1002/ddr.21686. Epub 2020 May 27. PMID: 32462699.
Wang J, Su P, Yang J, Xu L, Yuan A, Li C, Zhang T, Dong F, Zhou J, Samsom J, Wong AHC, Liu F. The D2R-DISC1 protein complex and associated proteins are altered in schizophrenia and normalized with antipsychotic treatment. J Psychiatry Neurosci. 2022;47(2):E134–47. https://doi.org/10.1503/jpn.210145. PMID: 35361701; PMCID: PMC8979657.
Escamilla R, Camarena B, Saracco-Alvarez R, Fresán A, Hernández S, Aguilar-García A. Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia. Neuropsychiatr Dis Treat. 2018;14:2981–7. PMID: 30464483; PMCID: PMC6223330.
Ye J, Ji F, Jiang D, Lin X, Chen G, Zhang W, Shan P, Zhang L, Zhuo C. Polymorphisms in dopaminergic genes in Schizophrenia and their implications in Motor deficits and antipsychotic treatment. Front Neurosci. 2019;13:355. https://doi.org/10.3389/fnins.2019.00355. PMID: 31057354; PMCID: PMC6479209.
Islam F, Men X, Yoshida K, Zai CC, Müller DJ. Pharmacogenetics-guided advances in antipsychotic treatment. Clin Pharmacol Ther. 2021;110(3):582–8. https://doi.org/10.1002/cpt.2339. Epub 2021 Aug 18. PMID: 34129738.
McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJ. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology. 2011;36(3):616–26. Epub 2010 Nov 24. PMID: 21107309; PMCID: PMC3055694.
Zhang JP, Robinson DG, Gallego JA, John M, Yu J, Addington J, Tohen M, Kane JM, Malhotra AK, Lencz T. Association of a Schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in First-Episode Psychosis. Schizophr Bull. 2015;41(6):1248–55. https://doi.org/10.1093/schbul/sbv116. Epub 2015 Aug 28. PMID: 26320194; PMCID: PMC4601717.
Ma L, Zhang X, **ang Q, Zhou S, Zhao N, **e Q, Zhao X, Zhou Y, Cui Y. Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis. Basic Clin Pharmacol Toxicol. 2019;124(1):94–104. https://doi.org/10.1111/bcpt.13111. Epub 2018 Sep 11. PMID: 30103286.
Han J, Li Y, Wang X. Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia. Neuropsychiatr Dis Treat. 2017;13:2935–43. https://doi.org/10.2147/NDT.S148824. PMID: 29255361; PMCID: PMC5722007.
Terzić T, Kastelic M, Dolžan V, Plesničar BK. Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia. Psychiatr Danub. 2016;28(2):127–31. PMID: 27287786.
Taraskina AE, Nasyrova RF, Zabotina AM, Sosin DN, Sosina КА, Ershov EE, Grunina MN, Krupitsky EM. Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines. BMC Psychiatry. 2017;17(1):394. https://doi.org/10.1186/s12888-017-1562-1. PMID: 29221470; PMCID: PMC5723030.
Zakharyan R, Ghazaryan H, Kocourkova L, Chavushyan A, Mkrtchyan A, Zizkova V, Arakelyan A, Petrek M. Association of Genetic Variants of Dopamine and serotonin in Schizophrenia. Arch Med Res. 2020;51(1):13–20. Epub 2020 Feb 18. PMID: 32086104.
Rajagopal VM, Rajkumar AP, Jacob KS, Jacob M. Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia. Pharmacogenet Genomics. 2018;28(1):31–5. https://doi.org/10.1097/FPC.0000000000000314. PMID: 29087970.
Tybura P, Samochowiec A, Beszlej A, Grzywacz A, Mak M, Frydecka D, Bieńkowski P, Mierzejewski P, Potemkowski A, Samochowiec J. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in patients with schizophrenia. Pharmacol Rep. 2012;64(3):528 – 35. https://doi.org/10.1016/s1734-1140(12)70848-4. PMID: 22814006.
Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh BZ, Snieder H, GROUP investigators. ;. Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. Eur Neuropsychopharmacol. 2012;22(9):625 – 31. https://doi.org/10.1016/j.euroneuro.2012.01.006. Epub 2012 Mar 3. PMID: 22386772.
Zhuo C, Cheng L, Li G, Xu Y, **g R, Li S, Zhang L, Lin X, Zhou C. COMT-Val158Met polymorphism modulates antipsychotic effects on auditory verbal hallucinations and temporal lobe gray matter volumes in healthy individuals-symptom relief accompanied by worrisome volume reductions. Brain Imaging Behav. 2020;14(5):1373–81. PMID: 30712251; PMCID: PMC7572342.
Werner FM, Coveñas R. Risk Genes in Schizophrenia and Their Importance in Choosing the Appropriate Antipsychotic Treatment. Curr Pharm Des. 2021;27(30):3281–3292. https://doi.org/10.2174/1381612827666210215151333. PMID: 33588721.
Saravani R, Galavi HR, Lotfian Sargazi M. Catechol-O-Methyltransferase (COMT) gene (Val158Met) and brain-derived neurotropic factor (BDNF) (Val66Met) genes polymorphism in Schizophrenia: a case-control study. Iran J Psychiatry. 2017;12(4):265–70. PMID: 29472953; PMCID: PMC5816916.
Ahmadi L, Kazemi Nezhad SR, Behbahani P, Khajeddin N,Pourmehdi-Boroujeni. M. Genetic variations of DAOA (rs947267 and rs3918342) and COMT genes (rs165599 and rs4680) in Schizophrenia and Bipolar I disorder. Basic and Clinical Neuroscience. 2018;9(6):429–38. https://doi.org/10.32598/bcn.9.6.429.
Torkaman-Boutorabi A, Ali Shahidi G, Choopani S, Reza Zarrindast M. Association of monoamine oxidase B and catechol-O-methyltransferase polymorphisms with sporadic Parkinson’s disease in an Iranian population. Folia Neuropathol. 2012;50(4):382-9. https://doi.org/10.5114/fn.2012.32368. PMID: 23319194.
Heydari M, Ghorbian S, Manizheh Sayyah Melli. and. The catechol-methyltransferase rs4680 G > A polymorphism is associated with uterine leiomyoma susceptibility. Gene, Cell and Tissue 6.1 (2019).
تأیید et al. بررسی فراوانی پلیمورفیسم rs4680 ژن COMT در عملکرد رقابتی ورزشکاران نخبهی رزمیکار زن و مرد ایرانی.مجله دانشکده پزشکی اصفهان41.705(2023):9–17.
Azadmarzabadi E. Detection of six novel de novo mutations in individuals with low resilience to psychological stress. PLoS ONE. 2021;16(9):e0256285.
https://aapp.org/guideline/essentials/antipsychotic-dose-equivalents.
Hajj A, Obeid S, Sahyoun S, Haddad C, Azar J, Rabbaa Khabbaz L, Hallit S. Clinical and Genetic Factors Associated with Resistance to treatment in patients with Schizophrenia: a case-control study. Int J Mol Sci. 2019;20(19):4753. https://doi.org/10.3390/ijms20194753. PMID: 31557839; PMCID: PMC6801865.
Zahari Z, Salleh MR, Zahri Johari MK, Musa N, Ismail R. A nested allele-specific multiplex polymerase chain reaction method for the detection of DRD2 polymorphisms. Malays J Med Sci. 2011;18(4):44–57. PMID: 22589672; PMCID: PMC3328935.
He Q, Shen Z, Ren L, Wang X, Qian M, Zhu J, Shen X. The association of catechol-O-methyltransferase (COMT) rs4680 polymorphisms and generalized anxiety disorder in the Chinese Han population. Int J Clin Exp Pathol. 2020;13(7):1712–9. PMID: 32782694; PMCID: PMC7414458.
Vereczkei A, Demetrovics Z, Szekely A, Sarkozy P, Antal P, Szilagyi A, Sasvari-Szekely M, Barta C. Multivariate analysis of dopaminergic gene variants as risk factors of heroin dependence. PLoS ONE. 2013;8(6):e66592. https://doi.org/10.1371/journal.pone.0066592. PMID: 23840506; PMCID: PMC3696122.
Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in Epidemiological studies. Commun Stat - Simul Comput. 2010;39(4):860–4. https://doi.org/10.1080/03610911003650383.
Yan P, Song M, Gao B, Wang S, Wang S, Li J, Fang H, Wang C, Shi J. Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in Chinese Han patients with schizophrenia. Psychiatry Res. 2020;293:113470. https://doi.org/10.1016/j.psychres.2020.113470. Epub 2020 Sep 20. PMID: 32992097.
Zhao M, Ma J, Li M, Zhu W, Zhou W, Shen L, Wu H, Zhang N, Wu S, Fu C, Li X, Yang K, Tang T, Shen R, He L, Huai C, Qin S. Different responses to risperidone treatment in Schizophrenia: a multicenter genome-wide association and whole exome sequencing joint study. Transl Psychiatry. 2022;12(1):173. https://doi.org/10.1038/s41398-022-01942-w. PMID: 35484098; PMCID: PMC9050705.
Ma J, Zhao M, Zhou W, Li M, Huai C, Shen L, Wang T, Wu H, Zhang N, Zhang Z, He L. 2021. Association between the COMT Val158Met polymorphism and antipsychotic efficacy in schizophrenia: An updated meta-analysis. Current neuropharmacology, 19(10), p.1780.
Sonia JA, Kabir T, Islam MMT, Kabir Y. Catechol-O-methyltransferase and dopamine receptor D4 gene variants: possible association with substance abuse in Bangladeshi male. PLoS ONE. 2021;16(2):e0246462. https://doi.org/10.1371/journal.pone.0246462. PMID: 33544778; PMCID: PMC7864466.
Sun Y, Zhou W, Chen L, Huai C, Huang H, He L, Qin S. Omics in schizophrenia: current progress and future directions of antipsychotic treatments. J Bio-X Res. 2019;2(04):145–52.
Hwang R, Tiwari AK, Zai CC, Felsky D, Remington E, Wallace T, Tong RP, Souza RP, Oh G, Potkin SG, Lieberman JA. Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(1):62–75.
Bilder R, Volavka J, Lachman H, et al. The Catechol-O-Methyltransferase polymorphism: relations to the Tonic–phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacol. 2004;29:1943–61. https://doi.org/10.1038/sj.npp.130054.
Płaza O, Gałecki P, Orzechowska A, Gałecka M, Sobolewska-Nowak J, Szulc A. Pharmacogenetics and Schizophrenia-Can Genomics improve the treatment with second-generation. Antipsychotics? Biomedicines. 2022;10(12):3165. https://doi.org/10.3390/biomedicines10123165. PMID: 36551925; PMCID: PMC9775397.
Acknowledgements
We would like to thank patients, their families and Salamat hospital personnel, especially Mrs Farokhmanesh for their co-operation in our study. We would like to thank Dr Morteza Mohammadzadeh from Iran University of Medical Sciences, for his assistance in a part of the statistical analysis. The study was supported by the Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences (CMRC-9726). The article is extracted from Narges Taheri thesis to obtain a master’s degree in genetics from Ahvaz Jundishapur University of Medical Sciences.
Funding
This work was supported by Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. [grant number CMRC-0001].
Author information
Authors and Affiliations
Contributions
N.T. conducted sample collection, all of the genetic experiments and statistical analysis. Furthermore, N.T. wrote the manuscript text. P.G. was the leader of the study and was involved in the guidance of all of the study’s steps. Also, P.G. edited the manuscript text. M.B., M.S. and R.P. were involved in finding appropriate patients with the study’s inclusion criteria and providing the possibility of sample collection. In addition, R.P. was the advisor of all the psychiatry sections of the study. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
We have no conflicts of interest to disclose.
Ethics approval and consent to participate
We confirm that all experiments were performed in accordance with relevant guidelines and regulations such as the Declaration of Helsinki.
Informed consent was received from all patients/legal representatives enrolled in this study.
The ethics committee of Ahvaz Jundishapur University of Medical Sciences approved this study (IR.AJUMS.MEDICINE.REC.1399.048).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Taheri, N., Pirboveiri, R., Sayyah, M. et al. Association of DRD2, DRD4 and COMT genes variants and their gene-gene interactions with antipsychotic treatment response in patients with schizophrenia. BMC Psychiatry 23, 781 (2023). https://doi.org/10.1186/s12888-023-05292-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12888-023-05292-9